title: HPV vaccines: state of the art.
abstract: Cervical cancer is one of the most common types of cancer in women worldwide and is frequent in relatively young women. In the last decades, its incidence has decreased following the implementation of screening programs, mainly in developed countries. Cervical screening programs, while successful if properly carried out, are difficult and expensive to implement, especially in developing countries. Advances in the understanding of the role of human papillomavirus (HPV) in the etiology of high-grade cervical lesions and cervical cancer have led to the development and evaluation of two prophylactic HPV vaccines. Vaccination against the HPV, which is the major cause of cervical cancer, is a significant step forward. This review article provides a summary of the most recent studies related with the development and efficacy of the two HPV vaccines.
authors.affiliation: Department of Biology, College of Science and Technology, Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, Pennsylvania 19122, USA.
authors.forename: Giuseppina
authors.initials: G
authors.lastname: D'Andrilli
authors.forename: Alessandro
authors.initials: A
authors.lastname: Bovicelli
authors.forename: Antonio
authors.initials: A
authors.lastname: Giordano
mesh_terms: D002986:Clinical Trials as Topic; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D030361:Papillomavirus Infections / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control; D053918:Papillomavirus Vaccines / Q000627:therapeutic use; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology
chemical_list: D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines; C510352:human papillomavirus vaccine, L1 type 16, 18